Kura Oncology, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing precision medicines for cancer patients. Headquartered in Redwood City, California, with additional research operations in Cambridge, Massachusetts, Kura focuses on small molecule therapies designed to target key genetic drivers of malignancy. Since its founding in 2010, the company has concentrated on identifying novel oncology targets and advancing molecules through preclinical research into human trials.
The company’s lead asset, tipifarnib, is a first-in-class farnesyltransferase inhibitor being evaluated in patients with HRAS mutant head and neck cancer, as well as in selected hematologic malignancies. Kura’s pipeline also features KO-539, a potent and selective menin inhibitor under investigation for MLL-r and NPM1-mutant acute myeloid leukemia, and KO-427, a covalent KRAS inhibitor targeting specific KRASG12 mutations. Additional programs include next-generation inhibitors of key signaling pathways and transcriptional regulators, reflecting Kura’s commitment to addressing unmet needs across solid tumors and blood cancers.
To broaden the reach of its therapies, Kura Oncology has established strategic partnerships and licensing agreements in major markets, including a collaboration with Sumitomo Dainippon Pharma for development and commercialization of tipifarnib in Asia. The company’s global footprint encompasses clinical trial sites throughout North America and Europe, enabling rapid patient access and robust data collection across diverse cancer populations.
Leadership at Kura Oncology is spearheaded by President and Chief Executive Officer Tony Febbraro, who brings extensive experience in oncology drug development and commercialization. Supported by a management team and board of directors with deep scientific and regulatory expertise, Kura is positioned to advance its targeted therapy portfolio through pivotal clinical milestones and regulatory interactions, with the goal of delivering new treatment options for patients facing challenging forms of cancer.
AI Generated. May Contain Errors.
